Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Passes Above 200 Day Moving Average – What’s Next?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)’s share price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $4.77 and traded as high as $5.10. Vanda Pharmaceuticals shares last traded at $4.95, with a volume of 658,725 shares trading hands.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on VNDA. HC Wainwright boosted their price target on Vanda Pharmaceuticals from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, February 18th. StockNews.com started coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They issued a “hold” rating for the company.

Vanda Pharmaceuticals Trading Down 0.6 %

The firm has a 50-day moving average of $4.60 and a 200-day moving average of $4.77. The stock has a market capitalization of $288.66 million, a price-to-earnings ratio of -15.47 and a beta of 0.69.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. The business had revenue of $53.19 million for the quarter, compared to analyst estimates of $51.00 million. On average, equities research analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were bought at an average cost of $5.02 per share, with a total value of $50,200.00. Following the transaction, the chief executive officer now owns 2,285,731 shares of the company’s stock, valued at approximately $11,474,369.62. This trade represents a 0.44 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders acquired 32,000 shares of company stock valued at $151,180. 8.90% of the stock is owned by insiders.

Institutional Trading of Vanda Pharmaceuticals

A number of hedge funds have recently modified their holdings of VNDA. BNP Paribas Financial Markets lifted its holdings in Vanda Pharmaceuticals by 1,184.6% in the third quarter. BNP Paribas Financial Markets now owns 62,238 shares of the biopharmaceutical company’s stock valued at $292,000 after acquiring an additional 57,393 shares during the period. FMR LLC lifted its stake in shares of Vanda Pharmaceuticals by 25.9% in the 3rd quarter. FMR LLC now owns 149,739 shares of the biopharmaceutical company’s stock valued at $702,000 after purchasing an additional 30,802 shares during the period. Massachusetts Financial Services Co. MA acquired a new position in shares of Vanda Pharmaceuticals in the 3rd quarter valued at $864,000. GSA Capital Partners LLP purchased a new stake in Vanda Pharmaceuticals during the third quarter worth $143,000. Finally, Barclays PLC grew its position in Vanda Pharmaceuticals by 128.2% during the third quarter. Barclays PLC now owns 154,297 shares of the biopharmaceutical company’s stock valued at $722,000 after buying an additional 86,677 shares during the period. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.